Evidence map›Paper›PMID 41486419›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Resilient Calvarial Bone Marrow Supports Retinal Repair in Type 2 Diabetes.

Bright Asare-Bediako, Sergio Li Calzi, Julia G Behnsen, Ram Prasad, Magdalena Blaszkiewicz, Yvonne Adu-Rutledge, Robert F Rosencrans, Jason L Floyd, Ashley Rennhack, Denise Stanford and 7 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bright Asare-BediakoDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Sergio Li CalziDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0001-8963-1519
Julia G BehnsenDepartment of Materials, Design and Manufacturing Engineering, School of Engineering, University of Liverpool, Liverpool, UK.
Ram PrasadDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Magdalena BlaszkiewiczDepartment of Neurological Surgery, The Ohio State University, Columbus, Ohio, USA.
Yvonne Adu-RutledgeDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Robert F RosencransDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jason L FloydDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Ashley RennhackDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Denise StanfordDepartment of Medicine, Cystic Fibrosis Research Center, The University of Alabama at Birmingham, Birmingham, USA.
Anna LinCollaborative Mass Spectrometry Core, Michigan State University, East Lansing, Michigan, USA.
Todd A LydicCollaborative Mass Spectrometry Core, Michigan State University, East Lansing, Michigan, USA.
Carl M SheridanDepartment of Eye and Vision Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Michael E BoultonDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Kristy L TownsendDepartment of Neurological Surgery, The Ohio State University, Columbus, Ohio, USA.
Julia V BusikDepartment of Biochemistry and Physiology, University of Oklahoma, Oklahoma City, Oklahoma, USA.
Maria B GrantDepartment of Ophthalmology and Visual Sciences, School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0002-6470-0255

Funding

Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID P OLSON · 2013 to 2026
$24.3M
Visual Phenotyping CoreP30EY003039 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul Douglas Gamlin · 1985 to 2026
$16.9M
NITRIC OXIDE IN THE PATHOGENESIS OF DIABETIC RETINOPATHYR01EY012601 · NEI · UNIVERSITY OF FLORIDA · PI Julia V Busik, Maria Bartolomeo Grant · 1998 to 2026
$9.6M
LXR as a Novel Therapeutic Target in Diabetic RetinopathyR01EY025383 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUSIK, JULIA V, GRANT, MARIA BARTOLOMEO · 2015 to 2024
$4.2M
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathyR01EY028037 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOULTON, MICHAEL EDWIN, FRAZIER, CHARLES J · 2017 to 2020
$1.9M
ACE2 on gut barrier dysfunction and BRB disruptionR01EY032753 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael Edwin Boulton, Maria Bartolomeo Grant · 2022 to 2026
$1.8M
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic RetinopathyR01EY028858 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BOULTON, MICHAEL EDWIN, GRANT, MARIA BARTOLOMEO · 2018 to 2021
$1.6M
National Eye Institute/National Institutes of Health (NEI/NIH) EY033620National Eye Institute/National Institutes of Health (NEI/NIH) P30EY003039National Eye Institute/National Institutes of Health (NEI/NIH) R01EY012601National Eye Institute/National Institutes of Health (NEI/NIH) R01EY025383National Eye Institute/National Institutes of Health (NEI/NIH) R01EY028037National Eye Institute/National Institutes of Health (NEI/NIH) R01EY028858National Eye Institute/National Institutes of Health (NEI/NIH) R01EY032753NEI NIH HHS P30 EY003039NEI NIH HHS R01 EY012601NIDDK NIH HHS P30 DK020572
6 · The paper itself

Abstract

Using micro-computed tomography, we identified a network of skull channels in the calvarium of type 2 diabetic (T2D) mice that remained structurally intact and numerically stable despite long-standing disease. The retention of calvaria bone marrow structural integrity was associated with preserved hematopoietic capacity under chronic diabetic conditions, which was not observed in the bone marrow of long bones. A distinctive feature of the calvarial bone marrow compartment was its direct exposure to cerebrospinal fluid (CSF), a property not shared by tibial bone marrow. To characterize the biochemical environment of the murine calvarium, we profiled oxysterols in CSF using mass spectrometry. The CSF exhibited elevated levels of neurotrophic and anti-inflammatory oxysterols, including 22-hydroxycholesterol (22-OHC) and 27-hydroxycholesterol (27-OHC). To assess whether this protective oxysterol signature was conserved in humans, we analyzed CSF samples from diabetic and non-diabetic individuals with obesity-associated idiopathic intracranial hypertension (IIH). Human CSF contained 7α-hydroxy-3-oxo-4-cholestenoic acid (7-HOCA), a metabolite of 27-OHC, supporting the conservation of this neuroprotective profile across species. Given the anatomical proximity of the calvarium to the eye, we hypothesized that calvaria bone marrow may serve as a reservoir for immune cells recruited to the injured or infected retina. The calvaria bone marrow was the predominant source of myeloid angiogenic cells (MACs) and neutrophils, mobilizing these cells at levels approximately 20-fold higher than long bones. These findings demonstrate that calvarial bone marrow plays a critical role in retinal immune defense, while maintaining both structural integrity and functional capacity despite chronic T2D.

Indexed as

Bone MarrowDiabetes Mellitus, Type 2Diabetic RetinopathyRetinaSkullAnimalsDiabetes Mellitus, ExperimentalDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMiddle AgedX-Ray Microtomographycalvarium marrowischemia‐reperfusionlong bonesmyeloid angiogenic cellsneutrophilsretinaskullstem/progenitor cells

Identifiers

PMID41486419
PMCPMC12955880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.